Curasight’s uTREAT Trial: A Promising Yet Cautious Step in Brain Cancer Diagnostics
Curasight’s initiation of the Phase I clinical trial for its uTREAT diagnostic platform targeting high-grade gliomas marks a noteworthy milestone in neuro-oncology diagnostics. However, as healthcare marketing professionals, we must…